進行性、上皮卵巣、原発性腹膜、または卵管がんのNab-PaclitaxelおよびBevacizumabと組み合わせたリラコリラント
進行性、上皮卵巣、原発性腹膜、または卵管がん(Bella)におけるNab-PaclitaxelおよびBevacizumabと組み合わせたリラコリラントの第2相研究
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
調査の概要
状態
詳細な説明
This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.
For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Corcept Therapeutics
- 電話番号:650-414-2314
- メール:corceptstudy557@corcept.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- 募集
- 004
-
-
California
-
Palo Alto、California、アメリカ、94304
- 募集
- 150
-
San Francisco、California、アメリカ、94109
- 募集
- 278
-
San Francisco、California、アメリカ、94143
- 募集
- 014
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- 032
-
-
Florida
-
Fort Myers、Florida、アメリカ、33901
- 募集
- 544
-
Miami Beach、Florida、アメリカ、33140
- 募集
- 335
-
West Palm Beach、Florida、アメリカ、33041
- 募集
- 543
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- 001
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55404
- 募集
- 518
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64132
- 募集
- 334
-
St Louis、Missouri、アメリカ、63110
- 募集
- 521
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、97102
- 募集
- 292
-
-
Ohio
-
Centerville、Ohio、アメリカ、45459
- 募集
- 304
-
-
Oregon
-
Eugene、Oregon、アメリカ、97401
- 募集
- 517
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15213
- 募集
- 127
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- 522
-
Norfolk、Virginia、アメリカ、23502
- 募集
- 300
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- 募集
- 121
-
-
-
-
-
Catania、イタリア、95126
- 募集
- 321
-
Milan、イタリア、20141
- 募集
- 122
-
Milan、イタリア、20159
- 募集
- 516
-
Pavia、イタリア、27100
- 募集
- 295
-
Rome、イタリア、00168
- 募集
- 124
-
Torino、イタリア、10128
- 募集
- 293
-
Treviso、イタリア、31100
- 募集
- 319
-
-
-
-
-
Badalona、スペイン、08916
- 募集
- 349
-
Barcelona、スペイン、08035
- 募集
- 115
-
Madrid、スペイン、28034
- 募集
- 114
-
Valencia、スペイン、46026
- 募集
- 330
-
Valencia、スペイン、46010
- 募集
- 558
-
-
-
-
-
Aachen、ドイツ、52074
- 募集
- 519
-
Berlin、ドイツ、10117
- 募集
- 255
-
Kempten、ドイツ、87439
- 募集
- 520
-
-
-
-
-
Lille、フランス、59000
- 募集
- 306
-
Nancy、フランス、54100
- 募集
- 307
-
Nice、フランス、06100
- 募集
- 310
-
Pierre-Bénite、フランス、69495
- 募集
- 324
-
Plérin、フランス、22190
- 募集
- 323
-
Toulouse、フランス、31059
- 募集
- 308
-
-
-
-
-
Brussels、ベルギー、1200
- 募集
- 109
-
Charleroi、ベルギー、6000
- 募集
- 326
-
Hasselt、ベルギー、3500
- 募集
- 325
-
Leuven、ベルギー、3000
- 募集
- 108
-
-
Belgium
-
Aalst、Belgium、ベルギー、9300
- 募集
- 328
-
-
-
-
-
Gdynia、ポーランド、81-519
- 募集
- 341
-
Siedlce、ポーランド、08-MO
- 募集
- 329
-
-
-
-
Gangnam-gu
-
Seoul、Gangnam-gu、韓国、06351
- 募集
- 396
-
-
Goyang-si
-
Gyeonggi-do、Goyang-si、韓国、10408
- 募集
- 397
-
-
Jongno-gu
-
Seoul、Jongno-gu、韓国、03080
- 募集
- 399
-
-
Seocho-gu
-
Seoul、Seocho-gu、韓国、06591
- 募集
- 523
-
-
Seodaemun-gu
-
Seoul、Seodaemun-gu、韓国、03722
- 募集
- 398
-
-
Songpa-gu
-
Seoul、Songpa-gu、韓国、05505
- 募集
- 403
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Arms A and B
- Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
- Arm A Only: Platinum-resistant disease
- Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
- Life expectancy of ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Able to swallow and retain oral medication
- 1 to 3 lines of prior systemic anticancer therapy
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Arm C
- Stage III or IV, recurrent, or metastatic endometrial cancer
- Life expectancy of ≥3 months
- ECOG performance status of 0 or 1
- Able to swallow and retain oral medication
- Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
- 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
- Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Exclusion Criteria:
Arm A and B
- Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- Untreated or symptomatic central nervous system metastases
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
Arm C
- Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
- Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab
In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
他の名前:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
実験的:Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab
In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
他の名前:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
実験的:Arm C: Relacorilant in Combination with Nab-Paclitaxel
In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
他の名前:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS)
時間枠:Date of first dose until PD or death, up to 18 months
|
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first. |
Date of first dose until PD or death, up to 18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
1つ以上の有害事象の患者の数
時間枠:最後の投与後最大30日後の最初の用量の日付
|
最後の投与後最大30日後の最初の用量の日付
|
|
|
Objective Response Rate (ORR)
時間枠:Date of first dose until PD or death, up to 18 months
|
To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1. |
Date of first dose until PD or death, up to 18 months
|
|
Best Overall Response Rate (BOR)
時間枠:Date of first dose until PD or death, up to 18 months
|
To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death. |
Date of first dose until PD or death, up to 18 months
|
|
Duration of Response (DOR)
時間枠:Time of first objective response until PD or death, up to 18 months
|
To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first. |
Time of first objective response until PD or death, up to 18 months
|
|
Clinical Benefit Rate (CBR)
時間枠:Week 24
|
To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1. |
Week 24
|
|
Overall Survival (OS)
時間枠:Date of first dose up to 6, 12, and 18 months
|
To evaluate the probability of OS survival at 6, 12, and 18 months. |
Date of first dose up to 6, 12, and 18 months
|
|
Area under the plasma concentration-time curve (AUC) of relacorilant
時間枠:On Cycle 1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 1 Day 8 (each cycle is 28 days)
|
|
Maximum plasma concentration (Cmax) of relacorilant
時間枠:On Cycle1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle1 Day 8 (each cycle is 28 days)
|
|
Trough plasma concentrations (Cmin) of relacorilant
時間枠:On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Danny Nguyen, MD、Corcept Therapeutics
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 内分泌系疾患
- 泌尿生殖器腫瘍
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 消化器系腫瘍
- 消化器系疾患
- 子宮の病気
- 生殖器疾患、女性
- 内分泌腺腫瘍
- 付属器疾患
- 性腺疾患
- 子宮腫瘍
- 腹膜疾患
- 腹部腫瘍
- 新生物
- 卵巣腫瘍
- 子宮内膜腫瘍
- 性器腫瘍、女性
- 腹膜腫瘍
- 卵管腫瘍
- 部位別新生物
- 卵巣疾患
- 卵管疾患
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- ベバシズマブ
- 130 nmアルブミンに縛られたパクリタキセル
- relacorilant
その他の研究ID番号
- CORT125134-557
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。